Alvogen, Inc. Sustainability Profile
Alvogen, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 2009, the company has rapidly expanded its operations across key regions, including North America, Europe, and Asia. Alvogen focuses on developing and manufacturing generic and specialty pharmaceuticals, with a strong emphasis on high-quality, affordable medications. The company is recognised for its innovative approach to drug development, particularly in the areas of oncology, respiratory, and central nervous system therapies. Alvogen's commitment to quality and efficiency has positioned it as a competitive force in the market, achieving significant milestones such as the successful launch of numerous generic products. With a robust portfolio and a dedication to improving patient access to essential medicines, Alvogen continues to make strides in the pharmaceutical landscape.
DitchCarbon Score
How does Alvogen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alvogen, Inc.'s score of 23 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alvogen, Inc.'s reported carbon emissions
Alvogen, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As a current subsidiary, Alvogen's climate initiatives and emissions data may be influenced by its corporate family relationships, but no specific cascading data from parent organisations has been provided. Without concrete emissions data or reduction initiatives, it is challenging to assess Alvogen's position within the pharmaceutical industry's climate commitments. In summary, Alvogen, Inc. has not disclosed any emissions data or reduction targets, indicating a potential area for future development in their sustainability strategy.
How Carbon Intensive is Alvogen, Inc.'s Industry?
How Carbon Intensive is Alvogen, Inc.'s Location?
Alvogen, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alvogen, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
